Can Melatonin Regrow Hair?

Melatonin is widely known as a sleep hormone, the compound produced by the pineal gland that regulates circadian rhythms. What is less widely known is that melatonin also has direct effects on hair follicles, independent of its role in sleep. Topical melatonin has been studied as a hair loss treatment, and the results are more substantive than most people expect from a supplement. This article explains the biology, reviews the clinical evidence, and addresses how melatonin fits into a hair loss protocol.

Melatonin's Role in the Hair Follicle

Melatonin receptors are present in human hair follicles. This was first established in a 2004 study by Fischer and colleagues, who demonstrated that melatonin receptor MT1 and MT2 are expressed in the outer root sheath and dermal papilla of human hair follicles. The discovery that follicles can respond to melatonin directly opened a line of research into its role in hair cycling.

Melatonin influences the hair follicle in several ways:

Antioxidant effects: Melatonin is a potent antioxidant that scavenges free radicals. The hair follicle matrix, with its rapid cell division, is particularly vulnerable to oxidative damage.

Melatonin protects follicle cells from oxidative stress, which can impair growth phase duration and follicle health.

Anagen promotion: Studies in animals have shown that melatonin can stimulate the transition of follicles from telogen (resting) to anagen (growth). In species that regulate seasonal coat growth through melatonin signaling, the hormone serves as a seasonal cue for follicle activation.

Anti-inflammatory effects: Melatonin reduces inflammation in multiple tissue types, including skin. Given the role of perifollicular inflammation in androgenetic alopecia, this is potentially clinically relevant.

Clinical Evidence for Topical Melatonin

The most significant clinical study on topical melatonin for hair loss was published in 2004 by

Fischer and colleagues — the same team that discovered melatonin receptor expression in the follicle. The randomized double-blind placebo-controlled trial enrolled 40 women with either androgenetic alopecia or diffuse hair loss.

Participants applied 0.1% melatonin solution or placebo to the scalp daily for six months. The results demonstrated:

• In women with androgenetic alopecia, melatonin significantly increased the ratio of anagen to telogen hairs (more follicles in the growth phase)
• Mean anagen rate increased significantly in the melatonin group vs. placebo
• Hair density improvements were most pronounced in the frontal and temporal regions
• No systemic side effects were observed

A larger observational study from 2012 enrolled 1,891 patients with androgenetic alopecia or diffuse hair loss who used a 0.1% topical melatonin solution for 90 days. At 30 days, 73.8% of patients showed improvement in hair texture. At 90 days, 75.1% reported reduced hair loss and 62.1% showed improvement in overall hair density.

Comparing Topical Melatonin to Standard Treatments

The evidence for topical melatonin is encouraging, but should be contextualized. The studies are smaller and less rigorous in design than the pivotal trials for finasteride and minoxidil.

This does not mean melatonin is ineffective. Rather, it means the evidence base is less mature.

As a result, melatonin is best viewed as a scientifically supported adjunct to standard care rather than a primary treatment for androgenetic alopecia.

Based on the available evidence, its strongest positioning is:

• As an adjunct to finasteride, minoxidil, or both — contributing antioxidant and anagen-promoting effects through a different mechanism
• In women with diffuse hair loss or telogen effluvium, where the evidence of anagen promotion is particularly relevant
• In patients who want to add a well-tolerated active ingredient with a favorable safety profile to their protocol
• In those who want an exclusively natural protocol, but only want to use clinically-studied natural ingredients

Oral Melatonin vs. Topical Melatonin

An important distinction: the evidence for melatonin as a hair loss treatment is specifically for topical application, not for oral melatonin supplements. Oral melatonin taken for sleep produces serum levels of about 0.1–0.7 ng/mL at standard doses. Whether this translates to meaningful follicle-level concentrations when delivered systemically is not established.

Topical melatonin concentrates the active ingredient at the scalp and follicle level. At 0.1%, the topical solution delivers a local concentration that is physiologically active at the melatonin receptors in the follicle.

Safety Profile

Topical melatonin has a well-documented favorable safety profile. In all published studies, no clinically significant adverse effects have been reported. There is no irritation, sensitization, or systemic uptake at concerning levels.

At 0.1% concentration, topical melatonin does not produce serum levels that would interfere with endogenous melatonin secretion or circadian rhythm regulation.

Where to Find Topical Melatonin

Topical melatonin for hair loss is not widely available. While some compounded topicals include it as an ingredient, these are often compounded alongside other supportive ingredients. And while many liquid formulations of melatonin exist, most are not specifically formulated for the scalp.

The Bottom Line

Melatonin has established receptor expression in human hair follicles and demonstrable effects on the anagen-to-telogen ratio in clinical trials. Topical 0.1% melatonin applied daily produces measurable improvements in hair density and reduced shedding in both men and women with androgenetic alopecia and diffuse hair loss.

Its mechanisms — antioxidant protection, anagen promotion, and anti-inflammatory activity — are complementary to those of finasteride and minoxidil, making it a viable adjunct in combination protocols. The evidence base is smaller than for first-line treatments, but it is a promising, science-backed ingredient.